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INTRODUCTION TO THE STUDY 
 
The concept of eHealth and its reality in daily medical practice fundamentally challenges our 
understanding of the practice and regulation of healthcare in terms of the relationship 
between practitioner and patient, between practitioner and institution as well as between 
institutions.  
 
In the traditional model, patient access to the healthcare delivery system has been limited to 
predetermined points of entry, such as through a primary care physician. From the entry 
point, the patient’s progress through the system has been relatively linear and often dictated 
by the health system’s reimbursement systems. Similarly, processes such as diagnosis, 
treatment and care have involved physical presence and personal interaction between 
providers and patients and of course, such physical presence requires some sort of 
identification (i.e., lack of anonymity).  
 
eHealth, however, is premised on a fundamentally new patient experience that is 
unconstrained by familiar points of entry and structures or traditional channels for delivering 
information or care. For one thing, anonymity or pseudonymity can be preserved much 
more easily. Not surprisingly, therefore, the eHealth revolution has as many serious 
implications for healthcare regulators and lawyers as for medical professionals. 
 
Although policy makers have noted at both European and national level that a lack of legal 
certainty about the use of eHealth tools and services exists, little has been done to study the 
issue in detail. Certain projects1 funded under the Framework Programmes have looked at 
the general legal issue concerning the use of information society technologies (IST), while 
others have included work packages looking at the legal aspects of a particular technology or 
application 2. Others still have looked at one particular issue, such as confidentiality, in 
greater detail3. However, it would seem that no work has been undertaken to date to look 
across the whole range of legal issue relevant to the use of IST tools and services in 
healthcare and to draw conclusions about the regulatory needs which may exist. 
 
As long ago as 1999, when the European Commission launched the eEurope initiative with 
the adoption of the Communication ‘eEurope – An Information Society for All’ 
(COM(1999)687 final, of 8.12.1999), it was noted that although the market for technological 
applications in the clinical domain was developing rapidly in Europe, and although the 
increase of health related information and education material available on the internet was of 
growing significance, the full exploitation of both sectors of eHealth was hindered by a lack 
of legal clarity and certainty. The Communication noted specifically that, in the clinical (including 
commercial) eHealth applications domain “uncertainty persists in the health telematics 
related industry about responsibility and data protection, the legality of providing on-line 
medical opinions as well as on-line pharmaceutical information and product supply.”  
 
                                                 
1 see for example  Legal IST-  FP6-IST   
2 see for examples NEXTGRID - FP6-IST or  EUROGENTEST - FP6-LIFESCIHEALTH and FP5- 
GEMSS 
3 see for example EUROSOCAP – Quality of Life Programme (FP5) 
Deleted: FP6
The issue was raised again in the 2004 Action Plan for a European eHealth Area 
(COM(2004)356). This stated that despite adoption of EU legislation on issues such as Data 
Protection (95/46/EC), Electronic Signatures (99/93/EC), eCommerce (2000/31/EC), 
Distance Contracting (97/7/EC) and the existing legislation on General Product Liability 
(92/59/EEC) and on Medical Devices (93/42/EEC), considerable uncertainty on the legal 
aspects of the use of eHealth applications, tools and services still continues. Accordingly the 
Action Plan proposes that by 2009 the European Commission shall “provide a framework 
for greater legal certainty of e-Health products and services liability within the context of 
existing product liability legislation.” 
 
In this context, the Commission called for the present study in order to establish a baseline 
report on existing EU level legislation, its impact on the delivery of eHealth and an analysis 
of the legal lacunae that may exist. The “Legally eHealth” study has looked in detail at three 
key regulatory aspects and has analysed the ways in which they might apply to eHealth 
situations: privacy, liability and competition. 
 
In this final report we look at which gaps might be said to exist - in how far is the regulatory 
framework that currently exists at European level sufficient to allow this important sector of 
European industry to flourish? We ask if in fact there are still significant barriers to the 
adoption and full exploitation of eHealth tools, systems and services to be found in a lack of 
relevant regulation. 
 
In keeping with the structure of the study this report looks first at the general legal issues in 
eHealth, then in some detail at the three areas discussed in the three core deliverables and 
finally at any other outstanding legal questions. 
SETTING THE SCENE ON OUR EHEALTH WORLD 
 
eHealth is a very broad term and encompasses many concepts. In this study we have taken 
the term to include the wide range of information technology based applications found in 
hospitals and primary care settings. These include administrative tools such as hospital 
information systems (HIS), summary records and discharge letters, clinical technical 
applications such as picture archiving and communications systems (PACS) as well as clinical 
support systems such as operating theatre systems (OR), decision support systems (DSS) and 
systems linking intuitions such as General Practitioners Systems, and electronic prescribing 
systems linking general practitioners with pharmacies (eRx).  At the heart of our eHealth 

















The stakeholders in eHealth World are classified into four groups of actors: citizens and 
patients; clinicians and care providers; payers, policy-makers and governments; and vendors, 
suppliers and commercial partners. All four groups of actors have highly significant but not 
always equal roles to play in healthcare. Our study in particular looks at the tensions that can 
arise between clinician and patient with respect to privacy and confidentiality or between 







































The Policy Context  
Before looking in some detail at the extent to which European law regulates eHealth it is 
important to step back and consider the role of Europe in health. For the European Union, 
which in 2007 celebrates its 50th Anniversary, public health policy is a relative new-comer 
arriving only in 1992 when the Maastricht Treaty included an article on “encouraging 
cooperation between Member States” and “if necessary, lending support to their actions” in 
public health. This legal competence was strengthened in 1997 with the Amsterdam Treaty 
when the EU was mandated to ensure “a high level of human health protection” in the 
“definition and implementation of all [Union] policies and activities” and to work with 
Member States to improve public health, prevent illness and “obviate sources of danger to 
human health” (article 152(1)). 
 
While the Amsterdam amendment extended the scope of public health related policy, it 
maintained the ‘subsidiarity principle’ for health which provides that harmonisation of 
Member Sates’ public health legislation is prohibited and the Union shall continue to respect 
fully the Member States’ responsibilities for the organisation and delivery of health services 
and medical care (article 152(4, 5)). 
 
The current situation is therefore that the European Union has a limited mandate to adopt 
public health policy whilst at all times respecting the right of Member States to adopt 
national level measures to regulate the organisation and delivery of health services. Thus 
even where EU level legislation on blood, organs and tissues is provided for in article 
152(4)(a), the Treaty highlights that such legislation shall not prevent any Member State from 
maintaining or introducing more stringent protective measures. 
 
Given that direct health policy is limited by the principle of subsidiarity it might be thought 
that there is rather little health services related law at EU level.  As already outlined, this 
study considers data protection law, consumer protection law and competition law, but it 
should not be thought that these three areas of law denote the limits of EU law and health.  
 
It is worth noting, for example, that European employment law has had a considerable 
impact on the organisation of health services in the EU in recent years. The Directive on the 
Organisation of Working Time, for example, which established the general principle that no 
employee can be obliged to work more than 48 hours a week and laid down minimum daily 
rest periods, has led many countries to adopt new contracts and procedures to govern the 
work of medical staff. Similarly the Directive on the Recognition of Professional 
Qualifications has simplified the mobility of health professionals across internal borders and 
has led some Member States to re-assess their medical education programmes.  
 
It is not, however, only employment related issues which impact on health; many other 
policy areas have had a significant impact on health and health services. The current debate 
at EU level on the approximation of the laws of the Member States relating to the labelling, 
presentation and advertising of foodstuffs requires all ingredients to be indicated on the label 
of food products and obliges manufacturers to list 12 potentially allergenic ingredients, in 
order to help consumers with health conditions or food allergies avoid specific ingredients or 
substances.  
 
However, the most well known legal aspect of health services in the European Union is 
related to the four fundamental freedoms of European citizens: the freedom of movement 
of goods, capital, services and persons. The free movements of goods and capital have 
almost been achieved, not least through the adoption of the single European currency. The 
full integration of the free movements of services and people has, however, been slower to 
achieve since they both have significant ramifications well beyond the economic sphere. 
 
The freedom of personal movement was initially construed as an objective applying only to 
workers, but as the European Union integration has deepened so a wider interpretation has 
come to prevail, not least through Directives which provide rights of residency for students 
and retired people and allow free movement of EU citizens provided they can show 
adequate financial means to support themselves. Through these provisions, it has become 
accepted that so long as an EU citizen has an independent income or a job he or she is 
entitled to settle in any EU Member State. Furthermore the European Court of Justice has 
stated that restrictions may only be imposed in individual cases where there is sufficient 
justification.  
 
The free movement of services is closely linked to the free movement of persons since it 
provides for professionals to practise anywhere in the EU in order to offer their services. 
The current rules lay down that, save for certain exceptions based on public policy, a 
provider of services is entitled to offer his or her services in an EU Member State other than 
his or her own, or to offer such services to someone who travels from another Member 
States in order to avail of services outside their normal country of residence. 
 
The development of the free movement of goods, services and people with respect to health 
related issues is found in the interpretation of the European Court of Justice of the rights 
accorded to European citizens under Regulation 1408/71 on the application of social 
security schemes to employed persons and their families moving within the Community.  
 
Since 1998 a series of highly significant cases have clarified the rights of European citizen to 
make use of health services and goods provided in Member States other than their usual 
State of residence. Of particular relevance are the Kohll case4, which provided that dental 
services are subject to the rules of free movement of services in articles 49 and 50 TEC, and 
the Decker case5 in which the Court held that prescription spectacles were covered by the 
provisions on the free movement of goods in articles 31 and 39 TEC. The later cases of 
Geraets-Smits/Peerbooms 6  and Mueller-Fauré/van Riet 7 addressed the issues of free 
movement to obtain hospital treatment out of state.  
 
The development began in 1998 when two Luxembourgish men purchased orthodontic 
treatment (Kohll) and spectacles (Decker) outside Luxembourg. In both cases the parties 
had purchased health services or goods in another EU Member State without obtaining the 
prior permission from their health insurance schemes provided as for in Regulation 1408/71 
                                                 
4 Case C-158/1996 of 28 April 1998 
5 Case C-120/1995 of 28 April 1998 
6 Case C-57/99 
7 Case C-385/99 
and then sought reimbursement of their expenses from their local Caisse de Maladie at 
normal Luxembourgish rates.  
 
Mr Kohll argued that the prior authorisation system restricted him from purchasing services 
in contravention of article 59 and 60 of the Treaty while Mr Decker maintained that his right 
to buy goods protected under article 30 was similarly violated. 
 
The European Court of Justice heard the cases jointly and determined that access to health 
services and the provisions of the Treaty covered health goods. The Court stated that while 
Regulation 1408/71 was valid, it as nonetheless secondary law, placing health services within 
the reach of the Treaty. Consequently, the Court held that the Treaty provisions on free 
movement of goods and services apply to health goods and services, thus providing a means 
for obtaining health goods and services in another state.  
 
Having established that principle, the Court next had to decide if the rules in 1408/71 that 
require the citizen to obtain prior authorisation before accessing such goods or services was 
a justifiable impediment to the general rule on the basis of public health or public policy. In 
each case, Luxembourg argued that the requirement of prior authorisation was a justifiable 
restriction on the basis that it was necessary to ensure the financial balance of the social 
security system and to safeguard to quality services and goods delivered.  
 
The Court dismissed the first argument on the basis that, since the reimbursement sought 
was at Luxembourgish rates, the local insurer would not have to pay out more than if the 
services or goods had been obtained in Luxembourg. The Court did accept, however, that in 
principle the need to ensure a balanced medical and hospital service open to all might justify 
limits on cross-border access to certain types of health services. Luxemburg’s second 
argument, that free access to health goods and services across internal borders should be 
limited on the basis of ensuring high quality, was dismissed on the grounds that the mutual 
recognition qualifications legislation provided adequate surety of the quality of health 
services providers in other EU countries. 
 
The following cases all tested the extent of the Court’s acceptance of the concept that prior 
authorisation for hospital-based health services could be justified and that therefore if a 
citizen failed to obtain such authorisation he or she could not seek reimbursement for any 
treatments obtained. 
 
The Geraets-Smits/Peerbooms case involved two Dutch claimants. Mrs Geraets-Smits had 
Parkinson’s disease and was treated in a specialist clinic in Germany. Her sickness insurance 
fund refused reimbursement of the costs incurred, on the ground that satisfactory and 
adequate treatment for that disease was available in the Netherlands and that the treatment 
provided in Germany conferred no additional advantage. Mr Peerbooms fell into a coma 
following a road accident. He received special intensive therapy in an Austrian clinic because 
he did not satisfy the requirements for the treatment in the Netherlands where it was 
available only to persons under the age of 25 years. Neither patient had obtained the prior 
consent for treatment outside the Netherlands provided for in the national legislation. 
 
In both cases the Court observed again that Member States are free to organise their social 
security systems, and recognised that a prior authorisation scheme could fit this need. In 
each case the Court decided however that the grounds given for refusing the prior 
authorisation were not justifiable and did not satisfy the principle of proportionality. The 
Court held that authorisation may be refused only if the patient can receive the same or 
equally effective treatment without undue delay from an establishment with which his or her 
sickness insurance fund has contractual arrangements. 
 
In the Mueller-Fauré/van Riet case, the Court further clarified that in determining undue 
delay for access to hospital care national authorities must take account of the patient’s actual 
medical condition and, where appropriate, the degree of pain or the nature of the patient’s 
disability, which might, for example, make it impossible or extremely difficult for him or her 
to carry out a professional activity, but also of his or her medical history. For the case of 
non-hospital care, the Court held that the principle of freedom to provide services precludes 
legislation that requires the insured to obtain prior authorisation for non-hospital care 
provided in another Member State by a non-contracted provider. 
 
On the matter of the level of costs to be reimbursed, the Vanbraekel8 case provided that 
national legislation must guarantee that an insured person who has been authorised to 
receive hospital treatment abroad receives a level of payment comparable to that which he or 
she would have received if he or she had received hospital treatment in his or her own 
Member State, even if in some cases this might result in a patient obtaining reimbursement 
at the national rate which is higher than the actual costs incurred in another EU Member 
State.  
 
It may be seen therefore from this array of cases that the European Court has decided quite 
firmly that: 
• Health services are services within the meaning of the Treaty and that therefore the 
rules on freedom of movement to obtain such services apply to European citizens 
seeking health services outside their own Member State; 
• Member States have a justifiable interest in limiting free access to health services in 
other Member States if to do so is necessary for planning and financial balance of 
health services; 
• Systems of prior authorisation may be used to facilitate planning of hospital based 
services, but not for non-hospital care; 
• Prior authorisation must be granted if equivalent treatment cannot be offered in a 
reasonable time having regard to the specific characteristics of the patient. 
 
 
                                                 
8 Case C-368/98 
LEGALLY EHEALTH – SETTING THE LIMITS 
 
The study notes the issues around freedom of movement as discussed above but 
concentrates in particular on three areas of European law rarely considered in depth with 





















































































































The “Legally eHealth” study in its three core chapters therefore considered the impact of 
data protection legislation, consumer protection and liability legislation and competition law.  
 
Deliverable 2 looks in detail at the requirements of EU and international level privacy and 
data protection legislation. It provides a thorough examination of the Data Protection 
Directive, Privacy in Electronic Communications as well as the European Convention of 
Human Rights and a number of recommendations of the Council of Europe. This legislation 
is then explored against the backdrop of a number of scenarios exploring data transfer for 
the purposes of better care provision both across European and international borders, as 
well as for commercial purposes. 
 
Deliverable 3 looks at the vexed issue of liability of eHealth goods and services. Whilst some 
of the services are rather simple eCommerce services transacted over websites, much more 
complex issues in terms multiple and split liability for services provided through a series of 
co-operating providers is also explored. 
 
Deliverable 4 considers the issues of trade and competition law that might apply to eHealth. 
Health services, in most European countries are provided to at least to some extent through 
direct taxation and compulsory health insurance. However, most eHealth services are 
offered through private enterprises and businesses and thus eHealth poses difficult questions 
concerning competition with public and private markets in situations where the distinction 
between the two is often very hard to establish. 
 
Having set out the core elements of those areas of law we now consider where the gaps 
might lie and how the European Commission should continue to develop policy and 
legislative initiatives which build on the existing framework to encourage the uptake of 
eHealth services across the European Union. 
RECOMMENDATIONS 
 
Recommendations on Data Protection 
Data Protection legislation is now well established in Europe, having its base in the Directive 
of 1995 which we discussed extensively in Deliverable 2. In respect to eHealth, the first 
point to note is that the current Directive takes a restrictive approach to health data 
processing – article 8 prohibits prima facie the processing of health data, but provides 
exceptions to the prohibition through patient consent, processing of data in the vital 
interests of the patient, processing for the purposes of medical diagnosis and care provision 
and in certain cases if there is a substantial public interest in such data processing.   
 
It should be noted that the Directive does not address any particular issues related to 
eHealth systems and services. However, the European Working Party on Data Protection, 
established under article 29 of the Directive and composed of the national data protection 
authority of each Member State, has recently acknowledged that some special rules may need 
to be adopted for key eHealth applications.  
 
To this end the Working Party issued in February 2007 a working paper looking at the 
applicability of data protection legislation to Electronic Health Record (EHR) systems. In its 
report, the Working Party noted in particular the limitation of the use of consent to permit 
the processing of heath data. The Working Party notes that if processing health data in an 
EHR system is the primary way of processing health data in a given health system, then a 
patient’s care may be compromised if he or she opts-out of such a system by not giving his 
or her consent to the creation of an EHR. Accordingly, consent should not be used, as it 
cannot be said to be truly and freely given. 
 
The remaining provisions setting aside the general prohibition on article 8 of the Directive 
can also be said to pose some problems – notably the idea that a patient ought to know the 
full finality of the use of data before his or her data may reasonably be used. eHealth tools 
such as EHRs, but also other tools used for healthcare functions such as care planning, 
decision support and risk assessment, are based on using the fullest range of data available to 
make the best informed choices.   
 
ISSUE 1: LEGAL UNCERTAINTIES IN DATA PROTECTION AND CONSENT 
Data subject consent may legitimate the processing of any data. Such consent is defined as 
any unambiguous, freely given, specific and informed indication of the data subject’s wishes 
by which the data subject signifies his or her agreement to personal data relating to him or 
her being processed (art. 2.h).  Medical data processing requires in addition that such consent 
be explicit because medical data is considered particularly sensitive. It is also permissible to 
process medical data without consent if it is in the vital interests of the data subject or 
another party and the data subject is physically or legally incapable of giving consent, or if it 
is done in the context of medical care provided by a healthcare professional with a legal 
obligation of professional confidentiality. 
 
RECOMMENDATION 1: DATA SUBJECT CONSENT  
As noted by the Data Protection Working Party there are some problems in using consent as 
a valid basis for processing data in eHealth applications. If eHealth applications are 
themselves integral to the way in which a good health service is provided, then requiring 
consent may in fact be denying the data subject a reasonable opportunity to withhold 
consent. If the creation of, for example, electronic medical records is a necessary and 
unavoidable consequence of the medical situation, withholding consent may be to the 
patient’s detriment. Therefore it would seem appropriate for the European Commission to 
co-ordinate the adoption of specific rules for the processing of health information to allow 
for proper balancing of patients’ and public health interests, without recourse to the concept 
of consent. 
 
ISSUE 2: LEGAL UNCERTAINTIES IN DATA PROTECTION AND SPECIFIED PURPOSE 
Data must be collected for specified and explicit purposes. This principle requires that, prior 
to possessing personal data, the controller has to define clearly and precisely the purpose(s) 
for which the data are to be processed. Moreover, the processing should be transparent.  
 
The data may be used only for the initial purpose and should not be re-used in a way 
incompatible with the initial purpose. Generally speaking, the purpose of the new processing 
has to be compared to the initial one(s) in order to assess whether there is a close 
relationship between them. A new purpose that is clearly different from the initial one(s) will 
be considered incompatible.  
 
It should be noted that, if further processing is deemed incompatible with the original 
purpose, further processing for historical, statistical or scientific purposes may be allowed if 
the data subject consents or if national legislation provides for such processing. 
 
RECOMMENDATION 2: SPECIFIED AND EXPLICIT PURPOSES 
In order to make optimal use of eHealth tools the European Commission should support 
the adoption of guidelines on the definition of the concept of finality of purpose that would 
provide an adequate balance between protection of the interests of the individual on the one 
hand and public health management and disease prevention on the other.  
 
If eHealth applications used for risk detection, disease monitoring and preventative care are 
to be fully realised, legal guidelines should be established that clarify the circumstances in 
which healthcare professionals can make further use of healthcare data in the interests of 
public health. Such guidelines should allow for secondary uses even where such uses could 
not have been foreseen at the time of data collection. 
 
While most Member States have already adopted guidelines at national level for such re-use 
of data for research or statistical purposes efforts should be made to harmonise these 
approaches across the EU so that meaningful cross-border work can support the health of 
all EU citizens.  
 
ISSUE 3: TECHNICAL AND ORGANISATIONAL SECURITY MEASURES 
Amongst the data controller’s duties are that he or she has the responsibility to protect the 
personal data he or she holds and therefore to take technical and organisational measures 
ensuring their security and confidentiality. 
 
RECOMMENDATION 3: TECHNICAL AND ORGANISATIONAL SECURITY MEASURES 
Efforts should be made to harmonise national standards on the technical and organisational 
measures of data security. Whilst the Data Protection Directive calls for such standards to be 
adopted, little has been done at a regulatory level to harmonise guidelines across the EU. 
 
While some technical standards for security have been adopted by the CEN (Comité 
Européen de Normalisation), concern still exists that these standards are not sufficiently 
integrated into daily medical practice to ensure that healthcare professionals feel secure 
enough to share data across EU borders in order to provide better care for their patients. 
 
Recommendations on eHealth and Product Liability 
Traditionally, medical liability is restricted to the relationship between the patient and the 
health practitioner (usually a doctor). When a patient is victim of medical negligence or of a 
medical error the patient will usually seek to introduce a civil or criminal lawsuit against the 
doctor.   
 
If medical liability continues to be considered as arising from the relationship between the 
patient and the health practitioner, the multiplication of intermediaries in the field of health 
services and the number of these with whom the patient has direct contact is changing the 
legal relationships between the various actors.  
 
Although general legal rules have been agreed to provide consumers with a legal guarantee of 
high quality products and services, the legal texts do not specifically address eHealth. The 
current EU level law is applied within the general context of service provision and product 
delivery, whether by traditional or electronic means. 
 
As a result it is often difficult to ascertain which EU level legislation applies to an eHealth 
product: is it considered a medical device, a software package, and does other legislation 
(e.g., on hazardous substances, for instance) also apply? 
 
ISSUE 1: SALE OF EHEALTH GOODS 
Sale of health goods, whether eHealth or traditional, will be covered by standard contracts 
for sale of goods. Thus, if the eHealth product fails to arrive or arrives late, the standard 
clauses in the contract will apply which will allow the purchaser to pay less or to return the 
goods. Similarly national legislation based on the EC Product Liability Directives will ensure 
that the purchaser has redress if the goods are not fit for the purpose for which they were 
sold.  
 
In general therefore in the eHealth arena, the purchaser of an eHealth good will need to 
make reference to the relevant national legislation based on Directive 1999/44 on the sale of 
consumer goods and associated guarantee. According to this Directive, when consumer 
goods are sold under a contract, the seller must deliver goods in conformity of the contract 
of sale. Moreover, when a commercial guarantee exists, the seller or producer who offered it 
will be legally bound to it. Anyone selling an eHealth product would have to comply with 
these rules, and conversely a purchaser of an eHealth product would have redress under 
them. 
 
RECOMMENDATION 1: SALE OF EHEALTH GOODS.  
It is not considered necessary to adopt specific eHealth sales of goods legislation. However it 
might be appropriate to consider the adoption of specific EU level guidelines on the sale of 
eHealth goods in order to encourage the adoption of EU wide markets in eHealth tools 
rather than the fragmented national level markets one sees currently. 
 
ISSUE 2: PRODUCT SAFETY 
Directive 2001/95 on general product safety imposes a general safety requirement for any 
product put on the market for consumers or likely to be used by them. The legislation 
requires that products are safe, and that producers provide consumers with the relevant 
information enabling them to assess the risks inherent in the product, particularly when they 
are not obvious, and take appropriate actions to avoid these risks (withdrawal from the 
market, warning to the market consumers, recall products already supplied…).  
 
RECOMMENDATION 2: PRODUCT SAFETY  
Although most of the legislation is well known to anyone operating in the business world, it 
is fair to say that eHealth products are still rather new and therefore little legal guidance 
exists on, for example, the type of information that is necessary and relevant to allow a 
purchaser to assess the risks of using a product.  
 
However, national authorities have been established to monitor product safety and to take 
appropriate measures to protect consumers. An information system has been put in place 
that imposes collaboration between distributors, producers and the national authorities but 
also between Member States and the European Commission (RAPEX).   
 
It would seem that at present this system is not well used for eHealth products. Accordingly, 
the European Commission should adopt policy tools to encourage the use of the RAPEX 
system for eHealth products.  
 
ISSUE 3: MEDICAL DEVICES  
According to the Directive 93/42 on Medical Devices, a ‘medical device’ is any instrument, 
apparatus, appliance, material or other article, whether used alone or in combination, 
including the software necessary for its proper application intended by the manufacturer to 
be used for human beings for the purpose of:  
• diagnosis, prevention, monitoring, treatment or alleviation of disease;  
• diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap; 
• investigation, replacement or modification of the anatomy or of a physiological 
process; 
• control of conception, 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its 
function by such means. 
 
The Directive requires that medical devices be designed and manufactured in such a way that 
their use do not compromise the safety and health of patients, users and other persons when 
properly installed, maintained and used in accordance with their intended purpose. When a 
Member State notes that a medical device conforming to the Directive compromises the 
health and/or safety of patients, users or, where applicable, other persons, it must take all 
appropriate interim measures to withdraw such devices from the market or prohibit or 
restrict their being placed on the market or put into service.  
 
Since electronic equipment and software is included in the definition of medical devices 
when they are manufactured or promoted for medical purpose, some eHealth products, such 
as monitoring devices, will be considered as medical devices under the European Medical 
Device legislation. However, eHealth tools used for the administration of general patient 
data will generally not be considered medical devices unless such a product (e.g., a PC, 
printer, screen, etc.) has had a specific medical purpose assigned to it.  
 
RECOMMENDATION 3: MEDICAL DEVICES 
More clarity is needed on the extent to which eHealth products are covered by Medical 
Devices legislation. Many of the currently available monitoring devices are covered only by 
general product liability, not by specific liability provision. It is suggested that further 
consultation on the application of medical devices legislation to eHealth tools takes place to 
establish if special guidelines should be issued.  
 
ISSUE 4: LIABILITY FOR EHEALTH SERVICES 
An eHealth service might be passive, such as delivering general medical information through 
a website, or might be active in giving medical advice or specific decision support to 
clinicians, or might involve the collection of biomedical data for remote monitoring by a 
clinician. Such a service might conceivably cause damage to someone relying on the service. 
A citizen might follow bad advice and fall ill, or even die; a clinician might follow the 
recommended procedure after using a decision support tool and might harm a patient; or a 
remote monitoring service might fail to transmit relevant data thereby putting a patient’s life 
a risk.  
 
There is currently no general European harmonisation of liability rules for services. 
Therefore, liability for services are governed by ordinary rules of contract law applicable in 
the Member States. 
 
However, when an eHealth service is a purely technical one and the provider is an Internet 
intermediary who transmits or stores third party information, such as a web-based store-and-
forward service for biosignal data for example, such a technical service provider will benefit 
from the rules of exoneration of liability established by the eCommerce Directive. These 
rules may minimise the risks for technical partners of eHealth service providers, who act as 
‘intermediaries’. Thus, web site hosting service will not be liable for the illegal sale of medical 
products made through an ePharmacy website.   
 
RECOMMENDATION 4:  LIABILITY FOR EHEALTH SERVICES 
The European Commission should consider supporting the adoption of EU level guidelines 
that would seek to identify the various parties involved in delivering eHealth services and 
establish the various liabilities that each party must accept. Such guidelines should be widely 
disseminated in order to develop healthcare practitioner and patient confidence in the use of 
eHealth services.  
 
In particular it should be investigated if specific guidelines on eHealth services could be 
drafted under the provisions for a Code of Conduct established in Directive 2000/31 on 
eCommerce. 
 
Recommendations on Competition Law 
The principles of free trade and competition are among the most important economic 
principles supported by the European Community. It is therefore not surprising the 
European Community has adopted a wide range of legislation to support competition 
through a legal system that prohibits any disloyal practices that restrict competition.   
 
The core of European competition law is found in the rules applying to private firms or 
“undertakings” in articles 81 and 82. Article 81 prohibits agreements and concerted practices 
with an anticompetitive object or effect on the market, while Article 82 prohibits abuse of a 
dominant position. Furthermore, article 86(2) states that the rules on competition also apply 
to public undertakings as long as the “application of such rules does not obstruct the 
performance, in law or in fact, of the particular tasks assigned to them.” 
 
The law encapsulated in the key articles above, as well as a wide range of ECJ case law, is 
established to allow fair and open competition between undertakings operating in the 
European Union and with a potential effect on trade between the Member States. 
 
ISSUE 1:  UNDERTAKING – WHEN IS AN ORGANISATION ACTING AS AN UNDERTAKING? 
The rules of competition law on abuse of dominant position and concerted practices are 
defined by the Treaty to apply only to those organisations classified as ‘undertakings’. The 
key question for purposes of healthcare providers is therefore whether any of the parties to 
an eHealth service are deemed to be undertakings and therefore subject to competition law. 
 
The recent case law at national and EU level has established that publicly funded health 
bodies may, in certain circumstances, be subject to competition law. However, the case law is 
unclear but would seem to provide that the same institution may, in some aspects of its 
conduct, be regarded as an undertaking (if it offers goods or services on the market) but in 
other aspects (such as contracting out certain care services) will not be considered an 
undertaking.  
 
This ambiguity in law will be unsettling for both public and private sector healthcare 
providers. Suppliers to the public sector, such as remote monitoring service providers, may 
feel that they have been left defenceless against large public purchasers, such as a national 
health system. However, public buyers have equally been left on shaky ground, especially 
those competing with private operators in the provision of goods and services. 
 
RECOMMENDATION 1: CLARIFICATION OF THE LAW ON UNDERTAKINGS 
The appropriate committees of the European Commission should be encouraged to examine 
the recent decisions of the ECJ on the application of articles 81 and 82 to healthcare 
providers in order to draw up clear guidelines establishing when a healthcare provider will be 
regarded as an undertaking and when not. 
 
Such guidelines should address the widest possible range of healthcare providers and 
suppliers, covering traditional and eHealth care. 
 
ISSUE 2: HEALTH SERVICES AS SSGI AND/OR SGEI 
The Treaty provides that an undertaking normally subject to the rules of competition law 
may be exempted from their application if it has been entrusted by a public body to provide 
a Service of General Economic Interest (SGEI) and if the application of the rules on 
competition would obstruct the performance of the particular tasks assigned to them. While 
it is left up to Member States to define the services they consider as SGEI, considerable lack 
of clarity still exists at EU level on the designation of health services. 
 
Recognising that many European health systems are provided through public funds, the 
European Commission has, in a number of communications, suggested that health services 
are not generally to be regarded as SGEI nor are they to be included in the wider definitions 
of Services of General Interest or Social Services of General Interest. The Commission has 
instead proposed that, because health services have such a unique character, special targeted 
rules on health services (of general interest) should be established. However, despite first 
raising this issue in 2001, the European Commission has yet to clarify the position of health 
services and their possible exemption from competition law.   
 
RECOMMENDATION 2: SPECIFIC CLARIFICATION OF HEALTH SERVICES WITH RESPECT 
TO SGEI 
It is recommended that the Commission adopt a communication or guidelines that set out 
clearly the circumstances under which a health service provider may make use of the 
provisions on SGEI in the Treaty and thus be exempted from competition law. Such 
guidelines should address the changing nature of health services, recognising that a wide 
range of actors from both public and private enterprises will be involved in the provision of 
both traditional and eHealth services. In order to encourage adequate investment in eHealth 
services, both public and private enterprises must have legal certainty on their position with 
respect to competition law.  
 
Recommendation on dissemination of legal knowledge 
eHealth products and services raise numerous new legal questions. Among these, the 
“Legally eHealth” study has examined in particular data protection, liability and consumer 
protection, and some aspects of competition law as being the most prominent. The results 
of the study have shown that European law provides the Member States with a significant 
number of harmonised answers and solutions regarding these topics.  
 
However, presentation of the study at various conferences and meetings has revealed that 
there is a lack of legal knowledge necessary to support the development and uptake of 
eHealth products and services. In other words, patients, medical practitioners, entrepreneurs, 
policy-makers, and others are not fully aware of the legal context in which eHealth products 
and services can and should be deployed. 
 
ISSUE: LACK OF KNOWLEDGE OF EHEALTH LAW 
The European Commission already supports various efforts to disseminate knowledge on 
information technology related law across the European Union, notably the LEFIS 
Thematic Network9 which seeks to develop, implement and consolidate a cross-national 
teaching and research infrastructure to respond to the needs and problems raised by the 
information and knowledge society. 
 
RECOMMENDATION: DISSEMINATING KNOWLEDGE ON EHEALTH LAW 
The European Commission should consider supporting a targeted tool for the dissemination 
of legal knowledge relative to eHealth products and services. As well as providing a 
repository of shared teaching material such as the LEFIS Thematic Network, this could: 
• support the development European guidelines based on real cases; 
• encourage the study of legal norms and rules applicable to eHealth products and 
services; 
• promote public information on legal norms and rules applicable about eHealth 
products and services. 
 
It is also worth noting that some other legal disciplines have started to establish successful 
virtual “European universities”. A good example is the French association ARFDM 
(Association de Recherche et de Formation en Droit Médical) which, in collaboration with 
the Paul Sabatier University (France, Toulouse) and many other European Universities as 
well as two major Canadian universities, organises a European Summer School on Medical 
Law. The first summer school took place in 2006 in Toulouse during the 16th World 
Congress on Medical Law and brought together 44 field specialists. A second session is due 
to take place in 2007 in Madrid.  
 
This kind of approach is an ideal format for disseminating legal knowledge and especially 
legal knowledge about European rules applicable to the healthcare sector. During the 
summer school, teachings focus on the basis of European medical law. 
 
It is recommended that the European Commission explore possibilities for supporting such 
summer schools dedicated to eHealth, in which clinicians and informaticians would have the 
opportunity to share information and learning not only on technological advances but also 
on legal complexities. 
 
Recommendation on an eHealth information infrastructure 
guidelines 
When eHealth services, such as electronic health records, first began to be provided by 
traditional healthcare providers such as hospitals and general practitioners, such products 
and services were supported by specifically dedicated telematic infrastructures (closed 
circuits and intranets), such as for example the MammoGrid infrastructure10.  
 
Today however, we are witnessing a new phase of eHealth in which numerous projects aim 
to exploit the existing information highway, the Internet, for linking disparate healthcare 
providers for occasional, ad hoc as well as pre-defined networking.  
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The use of such web-based applications is, however, creating a need for a permanent 
eHealth informatics infrastructure that can support any kind of eHealth products or services, 
and that will lead eventually to a dedicated “Health Information Highway”.  
 
The establishment of a dedicated Health Information Highway has many challenges, 
including in particular the challenge of interoperability between systems and applications and 
a service oriented architecture (SOA) that can accommodate a wide number of dispersed 
applications in a field where the number of such applications is growing daily. Such 
architecture use can loosely coupled with devices to support the requirements of business 
processes and users, in an environment where services are made available as independent 
applications that can be accessed without knowledge of their underlying platform 
implementation. This approach has gained good support in the health sector not least 
because it also provides greater interoperability and some protection from lock-in to 
proprietary vendor software. 
 
By definition, healthcare is an extremely fluid industry. Doctors, hospitals, insurance 
companies, and patients are subject to a never-ending series of regulatory changes, advances 
in treatment, procedural changes, and mergers and acquisitions. Each change requires an 
adaptation of systems, and each adaptation potentially impacts some or all systems. Point-to-
point integration quickly becomes costly and complex to maintain, and results in delays, 
inaccuracies, mountains of paperwork, and frustration for healthcare providers and 
consumers alike. The value of a SOA to the healthcare industry is that it enables health IT 
systems to speak the same language. If all systems can communicate using a common SOA 
framework, integration becomes less complex and IT can adapt to systems more rapidly.  
 
Presenting a powerful argument for SOA in health, Greg Mummah argued in an article in 
the Business Integration Journal that “SOA can provide the building blocks that help healthcare-
related IT organizations improve patient treatment and billing. It enables IT to focus on 
process improvement by removing system-to-system communication headaches. It makes 
organizations more adaptable to change”11. 
 
The challenges with the SOA and the adoption of a Health Information Highway are 
predominantly technical: interoperability and security remain huge challenges, which are 
being actively tackled by a number of European and national initiatives. However, the 
challenges are not purely technical. The adoption of such technologies also requires that the 
legal framework be properly adapted to the use of multiple applications by distributed actors. 
 
Although work on health information highways has been started in many Member States, it 
is questionable in how far these networks are fully compliant with Directive 95/46/EC on 
Data Protection and how much these different highways might lead to an interoperable 
international highway. 
 
ISSUE:  HEALTH DATA PROCESSING REQUIRES FINALITY OF PURPOSE 
At present each Member State has to draft specific legislation within the constraints of its 
duties within EU level Data Protection law. It is therefore suggested that the development 
                                                 
11 Greg Mummah;  “SOA Cures Healthcare Integration Headaches” in Business Integration Journal. Accessed at 
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and uptake of such network infrastructure could be greatly speeded up and much aided by 
specific EU level legislation that would set out harmonised rules for the free circulation of 
data within such a network infrastructure. 
 
The concept of such targeted data protection legislation is not new, as seen in Directive 
2002/58/EC on the processing of personal data and the protection of privacy in the 
electronic communications sector. It is argued therefore that an important next step for the 
legal clarification of eHealth would be taken in the adoption of a similar Directive (or a 
Recommendation) taking into account the characteristics of the underlying infrastructure 
supporting eHealth products and services. 
 
RECOMMENDATION:  A DIRECTIVE OR CODE OF CONDUCT ON PRIVACY AND HEALTH 
INFORMATION INFRASTRUCTURE 
A suggested Directive or Code of Conduct on Privacy and Health Information 
Infrastructure should be developed within the context Directive 95/46/EC and could take 
the form of either a dedicated Directive or could be an EU-level Code of Conduct to be 
approved by the European Working Part on Data Protection set up under article 29 of the 
Directive. Any such Directive or Code would be complementary to Directive 95/46/EC on 
Data Protection and Directive 2002/58/EC on Privacy and Electronic Commutations.  
 
The suggested Directive or Recommendation should include the following key elements:  
• define the actors involved in health information systems and their duties and rights; 
with respect to this, all activities within a Health Information Infrastructure should 
be monitored by a personal data protection official;  
• define security requirements for both the infrastructure and the eHealth products 
and services; 
• ensure the confidentiality of the personal data transiting through the infrastructure 
and through the eHealth products and services; 
• address the question of the use of the traffic data and other location data; 
• regulate the directories or registries required for the creation and the operating of the 
infrastructure and of the eHealth products and services (management of medical 
practitioners’ and patients’ personal data); 
• regulate the interoperability of the infrastructure and of eHealth products and 
services; 
• provide auditing measures; 
• provide special supervisory authorities at local, national and European levels 
considering the size of the information system; 
• describe the prior checking to take place before the operating of the infrastructure 
and of its products and services. 
 
The suggested Directive or Recommendation should also determine precisely: 
• the possible bases of legitimacy other than the data subject’s consent to create the 
infrastructure of those new information systems in healthcare, notably in terms of 
individual or collective benefits for the patient and for the community (guaranteed 
access to treatment, diagnosis, medicine, etc.) especially where private companies will 
be using these information systems to produce new scientific knowledge; 
• the appropriate safeguards required to allow for the further processing of personal 
data (and especially of medical data) for substantial public interests (without 
requiring the data subject’s consent) like scientific research (example of appropriate 
safeguard: a first coding by the initial data controller and a second coding by a 
trusted third party gathering all the data from the data controllers before sending 
them to the researchers); 
• the appropriate safeguards allowing for keeping the data for longer periods for 
scientific use; 
• the terms under which identification numbers or other identifiers may be used; 
• the exact consequences of the compliance with these safeguards notably in terms of 
data subject’s information and rights (to access, to rectify, to oppose, etc.); 
• the creation of effective judicial remedies, providing for compensation in case of 
breach of rules and for effective and dissuasive criminal sanctions; 
• the terms under which (coded) personal data may be transferred to third countries 
for scientific research.  
 
Although it may, of course, be decided that the time is not right for the adoption of a 
Directive dedicated to privacy in eHealth, it is recommended that at the very least a 
thorough investigation be undertaken on the way in which a select number of national health 
systems are currently addressing the issues outlined in the key points above, in order that a 
solid case for at least national level responses to the issues may be made.  
 
It should be noted, moreover, that the purpose of such a study would be not only to 
establish the need for EU level health data protection harmonisation, but would also provide 
a solid basis for the establishment of harmonised approaches to cross-border healthcare in a 
context in which, at present, no simple Treaty-based legitimation is available. 
 
Final Point: Impact Assessment on all future policy and 
Legislation for eHealth 
The “Legally eHealth” study has examined aspects of European law related to data 
protection, liability and consumer protection, and competition law. It has identified that a 
significant body of European law already addresses a number of the key legal issues in 
eHealth, even if not directly so. Data protection, for example, looks at the special needs of 
health data whilst recent changes to the medical devices directives examine the role of 
software within medical devices. It has been noted also that recent case law recognises that 
some aspects of competition law may apply to public and private enterprises operating in 
health and eHealth service provision. 
 
However, it is notable that despite the large numbers of communications on Services of 
General Interest, the Lisbon agenda and long-term care, as well as heated debates on health 
services with the Services Directive, little emphasis has been given to an impact assessment 
of the proposed legislative responses to health services in general and none have considered 
in depth their impact on eHealth services. Given however that the development of eHealth 
markets have been considered, for example by the Aho Report, as a major potential 
economic activity for Europe, further legal clarifications are necessary both to encourage the 
development of these markets in optimal conditions all the while respecting the unique 
nature of health services. 
 
eHealth is important for Europe: it can drive up service quality, improve patient safety, 
contain costs and facilitate access to healthcare. However, there is still great uncertainty in 
the eHealth actors, ranging across public bodies, big industry and small enterprises about the 
full legal implication of using and offering eHealth services.   
 
The “Legally eHealth” study has shown that a significant body of law already exists and is 
well adapted to responding to many of the questions raised by using and providing eHealth 
services. However, to drive up market confidence these issues must be made more clear to 
all users, not only through dissemination work, but also by focussed impact assessment 
which will highlight the eHealth aspects of future policy and legislation in order that such 
legislation is properly adapted to the needs of this sector.  
 
The final recommendation of the study is therefore to call for a mainstreaming of 
eHealth impact assessment across all European policy initiatives. 
 
